Clinical Trial Update: Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating an HMG-CoA reductase inhibitor for growth and bone abnormalities in children with Noonan syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noonan Syndrome

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Noonan Syndrome | Phase 3 | Status: COMPLETED